Anti-PD-L1 antibodies, compositions and articles of manufacture

US9920123B2 · kind B2 · utility

Assignee

• Genentech, Inc. · US

Inventors

• Bryan Irving · Woodside, US
• Henry Chiu · San Francisco, US
• Heather Maecker · Palo Alto, US
• Sanjeev Mariathasan · Millbrae, US
• Sophie M. Lehar · Berlin, US
• Yan Wu · Foster City, US
• Jeanne CHEUNG · Belmont, US

Key dates

• Filing date: Oct 26, 2016
• Grant date: Mar 20, 2018
• Expiry date: Oct 26, 2036

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.